annual-mental-health-2019-posters-abstracts

12 / 20

Find More Information @ March 2019 Conference Series LLC Ltd 51
conferenceseries LLC Ltd
6th World Congress on
Mental Health, Psychiatry and Wellbeing
March 20-21, 2019 | New York, USA
Rediscovering clozapine
Jason A. Gross
Pharmaceutical Executive,
Canada
In 1989, clozapine was
approved in the United
States for Treatment-Resistant
Schizophrenia (TRS), which after
thirty years of use is still the only
known treatment for TRS. In the
United States, there are more
than 3.5 million people living
with schizophrenia, of which
approximately 1 million have what
is known as treatment-resistant
schizophrenia. However, this
treatment option is only offered
to about 3% of eligible TRS
patients are receiving treatment
with clozapine. This lecture will
explore the: (i) The perceived
barriers to clozapine use (ii)
Recent advances in clozapine
care (iii) New technology for
monitoring patients with TRS
treated with clozapine (iv) Explore
best practices for patients with
TRS.
INTERNATIONAL JOURNAL OF EMERGENCYMENTAL HEALTH AND HUMAN RESILIENCE 2019, VOLUME 21
DOI: 10.4172/1522-4821-C2-030
ACCEPTED ABSTRACTS